Xeloda (capecitabine)

Information on this site is not intended as medical advice and should not be used as a substitute for consulting with qualified doctor.

Xeloda is a highly effective targeted oral chemotherapy offering patients a survival advantage when taken on its own or in combination with other anticancer drugs. Xeloda is converted to the active cancer-killing agent 5-FU (5-fluorouracil) directly inside the cancer cells, thus reducing damage to healthy cells. Xeloda tablets can be taken by patients in their own home, reducing the number of hospital visits.1

 

In Bangladesh Xeloda is approved for the following indications.2

  • Breast cancer

Xeloda in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline. Xeloda is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of a taxane and an anthracycline-containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.

  • Colon, colorectal cancer

- Xeloda is indicated as adjuvant treatment of patients with colon cancer.

- Xeloda is indicated for the treatment of patients with metastatic colorectal cancer.

  • Oesophagogastric cancer

Xeloda is indicated as first-line treatment of patients with advanced oesophagogastric cancer.

 

For more disease and medicine related queries you may discuss with your physician.

 

In Bangladesh Xeloda is available as

Film-coated tablets 500 mg

 

 

References

1. Global Website: Investors. Xeloda in combination with oxaliplatin shown to be effective in early colon cancer (2009, July 20). [Internet; cited 2018, December 03]. Retrieved from https://www.roche.com/investors/updates/inv-update-2009-07-20.htm

2. Xeloda Product Information _ FE-English Ro 09-1978 _ September 2018